# WEST

# Generate Collection

L6: Entry 6 of 7 File: DWPI May 29, 1996

DERWENT-ACC-NO: 1996-252856

DERWENT-WEEK: 199842

**COPYRIGHT 2002 DERWENT INFORMATION LTD** 

TITLE: Fruit juice supplemented with gamma or di:homo gamma linolenic acid - for treating e.g. hypertension, asthma, cancer

and prostatic diseases

INVENTOR: HORROBIN, DF

PATENT-ASSIGNEE:

ASSIGNEE CODE SCOTIA HOLDINGS PLC SCOTN

PRIORITY-DATA: 1994GB-0023625 (November 23, 1994)

## **PATENT-FAMILY:**

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 713653 A1	May 29, 1996	E	007	A23L002/52
AU 9537869 A	May 30, 1996		000	A23L001/29
NO 9504726 A	May 24, 1996		000	A23L002/02
CA 2163466 A	May 24, 1996		000	A23L002/52
FI 9505618 A	May 24, 1996		000	A23L002/52
ZA 9509843 A	August 28, 1996		015	A23L000/00
JP 08205832 A	August 13, 1996		006	A23L002/02
SG 35039 A1	February 1, 1997		000	A23L000/00
CN 1132607 A	October 9, 1996		000	A23L002/02
NZ 280468 A	August 26, 1998		000	A23L002/02

DESIGNATED-STATES: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

CITED-DOCUMENTS:DE 3213744; EP 275643 ; EP 366480 ; EP 609001 ; EP 611568 ; FR 2550445 ; GB 2209936 ; WO 8905101 ; WO 9117670

## APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
EP 713653A1	November 10, 1995	1995EP-0308080	
AU 9537869A	November 16, 1995	1995AU-0037869	
NO 9504726A	November 22, 1995	1995NO-0004726	
CA 2163466A	November 22, 1995	1995CA-2163466	
FI 9505618A	November 22, 1995	1995FI-0005618	
ZA 9509843A	November 20, 1995	1995ZA-0009843	
JP08205832A	November 21, 1995	1995JP-0302859	
SG 35039A1	November 22, 1995	1995SG-0001900	
CN 1132607A	November 23, 1995	1995CN-0121861	
NZ 280468A	November 15, 1995	1995NZ-0280468	

INT-CL (IPC): A23L 0/00; A23L 1/29; A23L 1/30; A23L 1/304; A23L 2/02; A23L 2/52; A61K 31/20; A61K 31/23; A61K 35/78

ABSTRACTED-PUB-NO: EP 713653A BASIC-ABSTRACT:

Fruit juice enriched or supplemented with gamma -linolenic acid (GLA) or dihomo gamma -linolenic acid (DGLA) comprises (i) 10-15 g (pref. 100 mg-2 g)/100 ml of GLA and/or DGLA; and (ii) opt. 1 mg-30 g (pref. 100 mg-2 g)/100 ml of arachidonic acid (AA), stearidonic acid (SA), eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA).

USE - GLA or <u>DGLA</u> is useful for the treatment or prevention of atopic eczema. It is admin. with: (i) calcium at 50-2000 mg/100 ml and opt. <u>EPA</u> for the treatment and prevention of osteoporosis; (ii) <u>EPA or DHA</u> for the prevention or treatment of rheumatoid or osteoarthritis; (iii) <u>EPA, DHA or AA</u> for the treatment of schizophrenia or alcoholism; or for the treatment and prevention of hypertension, coronary artery <u>disease</u> or peripheral <u>vascular disease</u>; (iv) other fatty acids or nutrients such as ascorbic acid or ascorbate at 10-2000 mg/100 ml for the treatment or prevention of asthma or diabetes and its complication s or for the supportive nutrition of patients with cancer; or (v) other fatty acids or nutrients such as zinc at 1-800 mg/100 ml for the treatment of prostatic <u>diseases</u> such as prostatic hypertrophy, (all claimed). The compsn. may also be useful for the treatment of skin disorders such as acne, inflammatory diseases such as systemic lupus erythematosus, Crohn's disease, ulcerative colitis, gastrointestinal disorders such as peptic ulcers and impaired renal function.

ADVANTAGE - The essential fatty acids are administered using a method which is attractive and pleasant for the consumer.

CHOSEN-DRAWING: Dwg.0/1

TITLE-TERMS: FRUIT JUICE SUPPLEMENTARY GAMMA DI HOMO GAMMA LINOLENIC ACID TREAT HYPERTENSIVE ASTHMA CANCER PROSTATE DISEASE

**DERWENT-CLASS: B05 D13 E17** 

CPI-CODES: B04-A10; B10-C04E; B14-C09; B14-E08; B14-E10; B14-F01E; B14-F02; B14-H01; B14-J01B3; B14-K01A; B14-M01A; B14-N01; B14-N07A; B14-N10; B14-S04; D03-H01G; D03-H01T2; E10-C04H;

### **CHEMICAL-CODES:**

```
Chemical Indexing M1 *01*
   Fragmentation Code
   M423 M431 M782 M903 Q211 V400 V406
Chemical Indexing M2 *02*
   Fragmentation Code
        H723 J0 J011 J1 J171 M225 M231 M262 M281
   M320 M416 M431 M782 M903 M904 P431 P526 P633 P723
   P738 P822 P943 Q211
   Specfic Compounds
   04255M
Chemical Indexing M3 *02*
   Fragmentation Code
        H723 J0
                 J011 J1 J171 M225 M231 M262 M281
   M320 M416 M431 M782 M903 M904 P431 P526 P633 P723
   P738 P822 P943 Q211
   Specfic Compounds
   04255M
Chemical Indexing M2 *03*
   Fragmentation Code
                 J011 J1 J171 M226 M231 M262 M281
        H723 J0
   M320 M416 M431 M782 M903 M904 P431 P526 P633 P723
   P738 P822 P943 Q211
   Specfic Compounds
   04489M
Chemical Indexing M3 *03*
   Fragmentation Code
        H723 J0
                 J011 J1 J171 M226 M231 M262 M281
   M320 M416 M431 M782 M903 M904 P431 P526 P633 P723
   P738 P822 P943 Q211
```

Record Display Form Specfic Compounds 04489M Chemical Indexing M2 \*04\* Fragmentation Code F012 F013 F014 F015 F113 H4 H403 H421 H482 H8 J522 KO L8 L818 L821 L832 L9 L942 L960 M280 M312 M321 M332 M343 M373 M391 M413 M431 M510 M521 M530 M540 M630 M782 M903 M904 P431 P714 P822 0211 V0 V330 Specfic Compounds 04454M Chemical Indexing M3 \*04\* Fragmentation Code F012 F013 F014 F015 F113 H4 H403 H421 H482 H8 J522 KO L8 L818 L821 L832 L9 M280 M312 M321 M332 M343 M373 M391 M413 M431 M510 M521 M530 M540 M630 M782 M903 M904 P431 P714 P822 Specfic Compounds 04454M Chemical Indexing M2 \*05\* Fragmentation Code F012 F013 F014 F015 F113 H4 H403 H421 H482 H8 J522 K0 L8 L818 L821 L832 L9 L942 L960 M280 M312 M321 M332 M343 M373 M391 M413 M431 M510 M521 M530 M540 M782 M903 M904 M910 P431 P714 P822 V330 Q211 V0 Specfic Compounds 00035M Registry Numbers 0035U Chemical Indexing M3 \*05\* Fragmentation Code F012 F013 F014 F015 F113 H4 H403 H421 H482 H8 J522 KO L8 L818 L821 L832 L9 L942 L960 M280 M312 M321 M332 M343 M373 M391 M413 M431 M510 M521 M530 M540 M782 M903 M904 M910 P431 P714 P822 0211 Specfic Compounds 00035M Registry Numbers 0035U Chemical Indexing M2 \*06\* Fragmentation Code A430 C810 M411 M431 M782 M903 M904 P633 Q211 Specfic Compounds 03035M Chemical Indexing M3 \*06\* Fragmentation Code A430 C810 M411 M431 M782 M903 M904 P633 Q211 Specfic Compounds 03035M Chemical Indexing M2 \*07\* Fragmentation Code H723 J0 J011 J1 J171 M226 M231 M262 M281 M320 M416 M431 M782 M903 M904 P421 P423 P446 P520 P522 P641 Q211

Chemical Indexing M3 \*07\*
Fragmentation Code

Specfic Compounds

04470M

#### Record Display Form

J011 J1 J171 M226 M231 M262 M281 Н7 H723 J0 M320 M416 M431 M782 M903 M904 P421 P423 P446 P520 P522 P641 Q211 Specfic Compounds 04470M Chemical Indexing M2 \*08\* Fragmentation Code J171 M226 M231 M262 M281 H723 J0 J011 J1 M320 M416 M431 M782 M903 M904 P421 P423 P446 P520 P522 P641 Q211 Specfic Compounds 04471M Chemical Indexing M3 \*08\* Fragmentation Code J171 M226 M231 M262 M281 H723 J0 J011 J1 M320 M416 M431 M782 M903 M904 P421 P423 P446 P520 P522 P641 Q211 Specfic Compounds 04471M Chemical Indexing M2 \*09\* Fragmentation Code J171 M226 M231 M262 M281 H723 J0 J011 J1 M320 M416 M431 M782 M903 M904 P446 P520 P522 P641 Q211 Specfic Compounds 04038M Chemical Indexing M3 \*09\* Fragmentation Code H723 J0 J011 J1 J171 M226 M231 M262 M281 M320 M416 M431 M782 M903 M904 P446 P520 P522 P641 0211 Specfic Compounds 04038M Chemical Indexing M2 \*10\* Fragmentation Code J171 M225 M231 M262 M281 H723 J0 J011 J1 M320 M416 M431 M782 M903 M904 Q211 Specfic Compounds 20700M Chemical Indexing M3 \*10\* Fragmentation Code J011 J1 J171 M225 M231 M262 M281 H723 J0 M320 M416 M431 M782 M903 M904 Q211 Specfic Compounds 20700M Chemical Indexing M2 \*11\* Fragmentation Code A220 C810 M411 M431 M782 M903 M904 P421 Q211 Specfic Compounds 03033M Chemical Indexing M3 \*11\* Fragmentation Code A220 C810 M411 M431 M782 M903 M904 P421 Q211 Specfic Compounds 03033M

# UNLINKED-DERWENT-REGISTRY-NUMBERS: 0035U

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1996-080032